Angiotensin II receptor blocker losartan exacerbates muscle damage and exhibits weak blood pressure-lowering activity in a dysferlin-null model of Limb-Girdle muscular dystrophy type 2B-Reference-Cited by-同舟云学术

Angiotensin II receptor blocker losartan exacerbates muscle damage and exhibits weak blood pressure-lowering activity in a dysferlin-null model of Limb-Girdle muscular dystrophy type 2B

Published:2019-08-12 Issue:8 Volume:14 Page:e0220903
ISSN:1932-6203
Container-title:PLOS ONE
language:en
Short-container-title:PLoS ONE

Author:

White Zoe^ORCID,Milad Nadia^ORCID,Tehrani Arash Y.,Chen William Wei-Han^ORCID,Donen Graham,Sellers Stephanie L.,Bernatchez Pascal

Publisher

Public Library of Science (PLoS)

Subject

Multidisciplinary

Reference60 articles.

2. Linkage of Miyoshi myopathy (distal autosomal recessive muscular dystrophy) locus to chromosome 2p12-14;K Bejaoui;Neurology,1995

3. Dysferlin, a novel skeletal muscle gene, is mutated in Miyoshi myopathy and limb girdle muscular dystrophy;J Liu;Nat Genet,1998

4. Proteomic identification of dysferlin-interacting protein complexes in human vascular endothelium;C Leung;Biochem Biophys Res Commun,2011

5. Defective membrane repair in dysferlin-deficient muscular dystrophy;D Bansal;Nature,2003

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Losartan and metabolite EXP3179 activate endothelial function without lowering blood pressure in AT2 receptor KO mice;European Journal of Pharmacology;2024-08

2. Update on anti-fibrotic pharmacotherapies in skeletal muscle disease;Current Opinion in Pharmacology;2023-02

3. Losartan metabolite EXP3179 is a unique blood pressure-lowering AT1R antagonist with direct, rapid endothelium-dependent vasoactive properties;Vascular Pharmacology;2022-12

4. Pleiotropic activation of endothelial function by angiotensin II receptor blockers is crucial to their protective anti-vascular remodeling effects;Scientific Reports;2022-06-13

5. Identification of candidate biomarkers and pathways associated with type 1 diabetes mellitus using bioinformatics analysis;Scientific Reports;2022-06-01